PI-88 and novel heparan sulfate mimetics inhibit angiogenesis.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Seminars in Thrombosis and Hemostasis

• Publication date

  2007-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1055/S-2007-982088PMID 17629854
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors

  2006cited by this paper
• Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies.

  2006cited by this paper
• Heparanase as a Target for Anticancer Therapeutics: New Developments and Future Prospects

  2006cited by this paper
• Therapeutic options to target angiogenesis in human malignancies

  2006cited by this paper
• Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.

  2006cited by this paper
• Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88).

  2005cited by this paper
• PI-88, a heparanase inhibitor showing promising evidence of patient benefit in phase II clinical trials.

  2005cited by this paper
• A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer

  2005cited by this paper
• Involvement of stromal proteoglycans in tumour progression.

  2004cited by this paper
• The low molecular weight heparan sulfate-mimetic, PI-88, inhibits cell-to-cell spread of herpes simplex virus.

  2004cited by this paper
• Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance.

  2003cited by this paper
• A novel early chorioallantoic membrane assay demonstrates quantitative and qualitative changes caused by antiangiogenic substances.

  2003cited by this paper
• Angiogenesis: Tumorigenesis and the angiogenic switch

  2003cited by this paper
• Heparin derivatives as angiogenesis inhibitors.

  2003cited by this paper
• Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia.

  2002cited by this paper
• Preparation and anticoagulant activity of the phosphosulfomannan PI-88.

  2002cited by this paper
• Quantitative and qualitative in vivo angiogenesis assay.

  2002cited by this paper
• Roles of heparan-sulphate glycosaminoglycans in cancer

  2002cited by this paper
• Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias

  2002cited by this paper
• Determination of the composition of the oligosaccharide phosphate fraction of Pichia (Hansenula) holstii NRRL Y-2448 phosphomannan by capillary electrophoresis and HPLC.

  2002cited by this paper
• Novel drug development opportunities for heparin

  2002cited by this paper
• Large-scale preparation of the oligosaccharide phosphate fraction of Pichia holstii NRRL Y-2448 phosphomannan for use in the manufacture of PI-88.

  2001cited by this paper
• Anticoagulant and Antiprotease Profiles of a Novel Natural Heparinomimetic Mannopentaose Phosphate Sulfate (PI-88)

  2001cited by this paper
• PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

  2000cited by this paper
• Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis.

  2000cited by this paper
• Angiogenesis in cancer and other diseases

  2000cited by this paper
• Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.

  1999influential reference

• Fucoidan: A marine-derived polysaccharide with therapeutic potential in atherosclerotic cardiovascular diseases: A review.

  2025cites this paper
• Chemical synthesis of glycan motifs from the antitumor agent PI-88 through an orthogonal one-pot glycosylation strategy

  2025cites this paper
• From Native Glycosaminoglycans to Mimetics: Design, Mechanisms, and Biomedical Applications

  2025cites this paper
• Block Synthesis and Step-Growth Polymerization of C-6-Sulfonatomethyl-Containing Sulfated Malto-Oligosaccharides and Their Biological Profiling

  2024cites this paper
• A heparanase-specific LYTAC degrader reinforces natural killer cell cytotoxicity within the tumor microenvironment

  2024cites this paper
• Potential roles of heparanase in cancer therapy: Current trends and future direction

  2023cites this paper
• Role of heparanase in sepsis‑related acute kidney injury (Review)

  2023cites this paper
• The Role of Heparan Sulfate in CCL26-Induced Eosinophil Chemotaxis

  2022cites this paper
• Bio-Multifunctional Sponges Containing Alginate/Chitosan/Sargassum Polysaccharides Promote the Healing of Full-Thickness Wounds

  2022cites this paper
• Importance of Heparan Sulfate Proteoglycans in Pancreatic Islets and β-Cells

  2022cites this paper
• New anti-angiogenic compound based on chemically modified heparin

  2022cites this paper
• From Cancer to COVID‐19: A Perspective on Targeting Heparan Sulfate‐Protein Interactions

  2021cites this paper
• Metastasis Prevention: Focus on Metastatic Circulating Tumor Cells

  2021cites this paper
• Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy

  2021cites this paper
• Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management

  2021cites this paper
• Oligosaccharides from fucosylated glycosaminoglycan prevent breast cancer metastasis in mice by inhibiting heparanase activity and angiogenesis.

  2021cites this paper
• Role of Heparanase in tumor progression: molecular aspects and therapeutic options.

  2020cites this paper
• Heparanase Inhibitors in Cancer Progression: Recent Advances.

  2020cites this paper
• Gamma-irradiation degraded sulfated polysaccharide from a new red algal strain Pyropia yezoensis Sookwawon 104 with in vitro antiproliferative activity.

  2020cites this paper
• Heparanase: Historical Aspects and Future Perspectives.

  2020cites this paper
• PI-88 and Related Heparan Sulfate Mimetics.

  2020cites this paper
• Molecular Aspects of Heparanase Interaction with Heparan Sulfate, Heparin and Glycol Split Heparin.

  2020cites this paper
• Receptor tyrosine kinases and heparan sulfate proteoglycans: interplay providing anticancer targeting strategies and new therapeutic opportunities.

  2020cites this paper
• Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds

  2019cites this paper
• Tumor-suppressive miR-299-3p inhibits gastric cancer cell invasion by targeting heparanase

  2019cites this paper
• Immunomodulatory and Therapeutic Potential of Marine Flora Products in the Treatment of Cancer

  2019cites this paper
• A synthetic glycosaminoglycan mimetic blocks HSV‐1 infection in human iris stromal cells

  2019cites this paper
• Dual Action of Sulfated Hyaluronan on Angiogenic Processes in Relation to Vascular Endothelial Growth Factor-A

  2019cites this paper
• Low molecule weight fucoidan mitigates atherosclerosis in ApoE (-/-) mouse model through activating multiple signal pathway.

  2019cites this paper
• Proteoglycan Chemical Diversity Drives Multifunctional Cell Regulation and Therapeutics.

  2018cites this paper
• Structural and conformational studies of the heparan sulfate mimetic PI-88

  2018cites this paper
• Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity

  2018cites this paper
• Structural features of heparanase-inhibiting non-anticoagulant heparin derivative Roneparstat.

  2017cites this paper
• Heparin Mimetics: Their Therapeutic Potential

  2017cites this paper
• A molecular dynamics-based algorithm for evaluating the glycosaminoglycan mimicking potential of synthetic, homogenous, sulfated small molecules

  2017cites this paper
• Gubenyiliu II Inhibits Breast Tumor Growth and Metastasis Associated with Decreased Heparanase Expression and Phosphorylation of ERK and AKT Pathways

  2017cites this paper
• Polysaccharides and their depolymerized fragments from Costaria costata: Molecular weight and sulfation-dependent anticoagulant and FGF/FGFR signal activating activities.

  2017influential citation
• HSV-1 interaction to 3-O-sulfated heparan sulfate in mouse-derived DRG explant and profiles of inflammatory markers during virus infection

  2017cites this paper
• Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications

  2017cites this paper
• Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides.

  2017cites this paper
• Surface Proteoglycans as Mediators in Bacterial Pathogens Infections

  2016cites this paper
• Process of hepatic metastasis from pancreatic cancer: biology with clinical significance

  2016cites this paper
• Heparanase: From basic research to therapeutic applications in cancer and inflammation.

  2016cites this paper
• Recent advances in the discovery of heparanase inhibitors as anti-cancer agents.

  2016cites this paper
• Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins

  2016cites this paper
• The Journal of Clinical Investigation

  2016cites this paper
• Heparan Sulfate: Biosynthesis, Structure, and Function.

  2016cites this paper
• Mechanisms of heparanase inhibitors in cancer therapy.

  2016cites this paper
• Anticoagulant and FGF/FGFR signal activating activities of the heparinoid propylene glycol alginate sodium sulfate and its oligosaccharides.

  2016cites this paper
• Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies

  2016cites this paper
• Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors

  2016cites this paper
• Effect of Spirogyra neglecta on the early stages of 1, 2-dimethylhydrazine-induced colon carcinogenesis in rats

  2016cites this paper
• Targeted Therapy for Hepatocellular Carcinoma.

  2016cites this paper
• A concise synthesis of single components of partially sulfated oligomannans.

  2015cites this paper
• Chemical Conjugate of Low Molecular Weight Heparin and Suramin Fragment Inhibits Tumor Growth Possibly by Blocking VEGF165.

  2015cites this paper
• Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation.

  2015cites this paper
• Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells

  2015cites this paper
• Maturation finale des lymphocytes B : de la commutation de classe aux conséquences pathologiques de la production d'immunoglobulines anormales

  2015cites this paper
• Size Controlled Heparin Fragment-Deoxycholic Acid Conjugate Showed Anticancer Property by Inhibiting VEGF165.

  2015cites this paper
• Advanced nanocarriers based on heparin and its derivatives for cancer management.

  2015cites this paper
• Diversity of Heparan Sulfate and HSV Entry: Basic Understanding and Treatment Strategies

  2015cites this paper
• Implications of CXCR4/CXCL12 Interaction for Cancer Stem Cell Maintenance and Cancer Progression

  2015cites this paper
• Synthesis of glycosaminoglycan mimetics through sulfation of polyphenols.

  2015cites this paper
• Recent Advances in the Prevention of Hepatocellular Carcinoma Recurrence

  2014cites this paper
• Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican‐3 for liver cancer therapy

  2014cites this paper
• COMBINED NMR/LC-MS APPROACH FOR STRUCTURAL CHARACTERIZATION OF HEPARINS AND NON-ANTICOAGULANT GLYCOL-SPLIT HEPARINS

  2014cites this paper
• Synthetic, Non-saccharide, Glycosaminoglycan Mimetics Selectively Target Colon Cancer Stem Cells

  2014cites this paper
• The potential of heparanase as a therapeutic target in cancer.

  2014cites this paper
• Resection of hepatitis B virus-related hepatocellular carcinoma: evolving strategies and emerging therapies to improve outcome.

  2014cites this paper
• Targeted therapies for medulloblastoma: understanding the mechanisms of drug resistance and exploring new peptide-based therapeutics

  2013cites this paper
• Glycobiology in cardiometabolic homeostasis

  2013cites this paper
• Synthesis and anti-angiogenetic activity evaluation of N-(3-aryl acryloyl)aminosaccharide derivatives.

  2013cites this paper
• Heparan sulfate inhibitors and their therapeutic implications in inflammatory illnesses

  2013cites this paper
• UvA-DARE ( Digital Academic Repository ) Glycobiology in cardiometabolic homeostasis

  2013cites this paper
• Relationship between structural flexibility and function in the C-terminal region of the heparin-binding domain of VEGF165.

  2013cites this paper
• 1 The PG 500 Series : Novel Heparan Sulfate Mimetics as Potent Angiogenesis and Heparanase Inhibitors for Cancer Therapy

  2013cites this paper
• Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site.

  2013cites this paper
• Fucoidan Inhibits the Growth of Hepatocellular Carcinoma Independent of Angiogenesis

  2013cites this paper
• Synthesized Multiple Antigenic Polypeptide Vaccine Based on B-Cell Epitopes of Human Heparanase Could Elicit a Potent Antimetastatic Effect on Human Hepatocellular Carcinoma In Vivo

  2013cites this paper
• New targets for glycosaminoglycans and glycosaminoglycans as novel targets

  2013cites this paper
• Glycosaminoglycan and chemokine/growth factor interactions.

  2012cites this paper
• Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis.

  2012cites this paper
• Heparin - A Century of Progress

  2012cites this paper
• Downregulation of heparanase by RNA interference inhibits invasion and tumorigenesis of hepatocellular cancer cells in vitro and in vivo.

  2012cites this paper
• Novel 1,4-benzoxazine and 1,4-benzodioxine inhibitors of angiogenesis.

  2012cites this paper
• Multiple Antigenic Peptides Based on H-2Kb–Restricted CTL Epitopes from Murine Heparanase Induce a Potent Antitumor Immune Response In Vivo

  2012cites this paper
• Glycosaminoglycans: key players in cancer cell biology and treatment

  2012cites this paper
• Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model

  2012cites this paper
• Glycosaminoglycan analogs as a novel anti-inflammatory strategy

  2012cites this paper
• Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-β-D-glucuronidase (heparanase).

  2012cites this paper
• Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides.

  2012cites this paper
• FQBSBOTVMGBUFBOEIFQBSBOBTF QMBZLFZSPMFTJONPVTF βDFMMTVSWJWBM BOEBVUPJNNVOFEJBCFUFT

  2012cites this paper
• Developing drugs from sugars: current state of glycosaminoglycan-derived therapeutics

  2012cites this paper
• A focused sulfated glycoconjugate Ugi library for probing heparan sulfate-binding angiogenic growth factors.

  2012cites this paper
• Preclinical Development Multiple Antigenic Peptides Based on H-2 Kb – Restricted CTL Epitopes fromMurineHeparanase Induce aPotent Antitumor Immune Response In Vivo

  2012cites this paper
• Heparan sulfate and heparanase play key roles in mouse β cell survival and autoimmune diabetes.

  2012cites this paper
• Heparin Impairs Angiogenesis through Inhibition of MicroRNA-10b*

  2011cites this paper
• Glycosaminoglycans-binding cytokines and tumor: Glycosaminoglycans-binding cytokines and tumor

  2011cites this paper
• Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival

  2011cites this paper
• Challenges and Successes in Developing Effective Anti-angiogenic Agents

  2011cites this paper